

- Yepes-Cortés C., Cardenas-Moreno I., Daza-Arnedo R., Feriz-Bonelo K., Yama-Mosquera E., Ramírez-Rincón A., Castillo-Barrios G., Suarez-Rodriguez A., Carreño-Jiménez J., and Builes-Montañó C., 2025, Combining GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes mellitus: a scoping review and expert insights for clinical practice utilizing the nominal group technique, *Diabetes Therapy*, 16: 813-849.
<https://doi.org/10.1007/s13300-025-01722-x>
- Zatterale F., Longo M., Naderi J., Raciti G., Desiderio A., Miele C., and Beguinot F., 2020, Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes, *Frontiers in Physiology*, 10: 1067.
<https://doi.org/10.3389/fphys.2019.01607>
- Zhang S., Yu B., Xu J., Jin S., Li Y., Bing H., Li J., X., Zhang X., and Zhao L., 2025, Quantitative comparison of glucagon-like peptide-1 receptor agonists on weight loss in adults: a systematic review and model-based meta-analysis, *Diabetes Technology and Therapeutics*, 27: 422-429.
<https://doi.org/10.1089/dia.2024.0533>
- Zhao X., Wang M., Wen Z., Lu Z., Cui L., Fu C., Xue H., Liu Y., and Zhang Y., 2021, GLP-1 receptor agonists: beyond their pancreatic effects, *Frontiers in Endocrinology*, 12: 721135.

Disclaimer/Publisher's Note



The statements, opinions, and data contained in all publications are solely those of the individual authors and contributors and do not represent the views of the publishing house and/or its editors. The publisher and/or its editors disclaim all responsibility for any harm or damage to persons or property that may result from the application of ideas, methods, instructions, or products discussed in the content. Publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
